Matinas BioPharma (NYSE:MTNB) Holdings, Inc. (NYSE American:MTNB), a pharmaceutical company specializing in the development of drug delivery technologies with a current market capitalization of $3 ...

In a recent Special Meeting held on Monday, Matinas BioPharma (NYSE:MTNB) Holdings, Inc. received shareholder approval on several significant proposals. The meeting, which was convened on April 4 ...

Matinas BioPharma's gross profit margin for fiscal years ending December 2019 to 2023 averaged -13,422.8%. Matinas BioPharma's operated at median gross profit margin of -8,968.8% from fiscal years ...

Matinas BioPharma Hldgs (AMEX:MTNB) shares moved upwards by 14.85% to $0.58. The market value of their outstanding shares is at $126.0 million. VYNE Therapeutics (NASDAQ:VYNE) stock increased by ...

Matinas BioPharma (MTND) filed a prospectus for the offer and sale of 16.89M shares of common stock by the selling stockholders. This preliminary prospectus is not an offer to sell these securities.

Matinas BioPharma's gross profit margin for fiscal years ending December 2019 to 2023 averaged -13,422.8%. Matinas BioPharma's operated at median gross profit margin of -8,968.8% from fiscal years ...

In a recent Special Meeting held on Monday, Matinas BioPharma (NYSE:MTNB) Holdings, Inc. received shareholder approval on several significant proposals. The meeting, which was convened on April 4, ...

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...

1 Day MTNB 12.61% DJIA 0.05% Russell 2K 0.00% Health Care/Life Sciences -0.16% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...